RAPT Director Dumps 30,000+ Shares as GSK Merger Closes—Insiders Cash In on $58‑Share Premium

Insider Sales Amid a Merger: What RAPT Investors Should Note

RAPT Therapeutics’ board‑member Ashley L. Dombkowski sold 4,956 shares of common stock and 25,000 director stock‑option contracts on March 3, 2026—right after the company announced a $58‑per‑share tender offer from GlaxoSmithKline‑related entities. The shares were sold at the tender price, effectively converting her RSUs and options into cash. The move coincides with the completion of the merger, which has taken RAPT from an independent biotech to a wholly owned subsidiary of the GSK umbrella.

Implications for the Stock and the Company’s Future

The timing of the sale signals that insiders are cashing in their positions in anticipation of, or in reaction to, the merger. For shareholders, the bulk of the sale—over 30 000 option shares plus the RSU‑converted cash—reduces the concentration of insider holdings. In the long run, a smaller insider stake may make the stock more attractive to external investors who prefer less insider influence. However, the immediate effect is a surge of selling pressure, which could depress the share price if the market interprets the sales as a lack of confidence in RAPT’s standalone prospects.

Beyond the mechanics, the merger itself is a watershed event. The $58‑per‑share price is a significant premium over the 52‑week low of $5.66 and represents a 541 % annual gain, underscoring how highly valued RAPT’s pipeline is. The deal places RAPT under GSK’s strategic umbrella, providing access to vast R&D resources and a global commercialization network—potentially accelerating the company’s immunology and oncology initiatives. Investors will now be looking at how quickly RAPT can integrate into GSK’s structure and whether the partnership translates into tangible revenue growth.

Dombkowski’s Transaction Profile

Historically, Dombkowski has followed a pattern of buying and selling the same number of shares. In late January 2026 she purchased 4,956 shares, and on March 3 she sold that same block, aligning the sale with the merger announcement. This “buy‑sell” cycle is typical of a director who is balancing personal cash needs with the company’s timing. Her option sales—25,000 contracts—mirror the same strategy; the options were originally granted to reward her as a director and were now liquidated as the merger closed. The lack of any other major insider activity by Dombkowski in the last year suggests that the March 3 transactions are driven primarily by the merger’s financial terms rather than a broader strategic shift.

What Investors Should Watch

1. Merger Completion Metrics – Investors should track whether the tender offer and merger terms are fully realized, including cash disbursement schedules and any post‑merger integration milestones.
2. RAPT’s Pipeline Status – A key risk is whether the company’s drug candidates meet the accelerated development timelines expected under GSK’s umbrella.
3. Shareholder Composition Post‑Merger – The reduction in insider holdings could open the door for new institutional investors, potentially stabilizing the stock price in the short term.
4. Regulatory Approvals – As a biotech merger, any antitrust or FDA‑related hurdles could delay or dilute the benefits anticipated by the deal.

In summary, Dombkowski’s insider sales are a textbook example of a director cashing out at a favorable merger price. For investors, the broader question is whether RAPT’s integration into GSK will sustain the stock’s impressive annual growth and unlock the company’s therapeutic potential—an outcome that could justify the $58‑share premium paid today.